XERS240517C1500
- 0.95
- +0.40+72.73%
Xeris Pharmaceuticals Newsroom
Analysts Offer Insights on Healthcare Companies: Xeris Pharmaceuticals (XERS), AMN Healthcare Services (AMN) and 4D Molecular Therapeutics (FDMT)
Socket Mobile And 3 Other Stocks Under $3 Insiders Are Buying
The Dow Jones index closed higher by over 100 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders in
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Just Reported And Analysts Have Been Lifting Their Price Targets
The analysts might have been a bit too bullish on Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), given that the company fell short of expectations when it released its first-quarter results last week.
Xeris Pharmaceuticals(XERS.US) Director Buys US$10,314 in Common Stock
$Xeris Pharmaceuticals(XERS.US)$ Director Schmid John P. purchased 5,400 shares of common stock on May 10, 2024 at an average price of $1.91 for a total value of $10,314.Source: Announcement What is s
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q1 2024 Earnings Call Transcript
Xeris Biopharma Price Target Cut to $3.00/Share From $4.00 by Piper Sandler
Xeris Biopharma Price Target Cut to $3.00/Share From $4.00 by Piper Sandler
Express News | Piper Sandler Reiterates Overweight on Xeris Biopharma Holdings, Lowers Price Target to $3
Xeris Biopharma Holdings Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/10/2024 57.07% Piper Sandler $4 → $3 Reiterates Overweight → Overweight 03/28/2024 161.78% Oppenheimer
Xeris Pharmaceuticals (XERS) Receives a Buy From Oppenheimer
Strong Operational Performance and Promising Prospects Affirm Buy Rating for Xeris Pharmaceuticals
Xeris Pharmaceuticals | 10-Q: Quarterly report
Xeris Biopharma Holdings, Inc. (XERS) Q1 2024 Earnings Call Transcript
Xeris Biopharma Holdings, Inc. (XERS) Q1 2024 Earnings Call Transcript
Craig-Hallum Reaffirms Their Buy Rating on Xeris Pharmaceuticals (XERS)
Express News | Xeris Biopharma Holdings Inc - Tightening Full-Year 2024 Total Revenue Guidance to $175M-$200M
Express News | Xeris Biopharma Raises FY24 Total Revenue Outlook To $175M-$200M Vs. 184.43M Estimate (Prior View: $170M-$200M)
Xeris Biopharma Holdings Q1 EPS $(0.14) Misses $(0.12) Estimate, Sales $40.64M Miss $41.81M Estimate
Xeris Biopharma Holdings (NASDAQ:XERS) reported quarterly losses of $(0.14) per share which missed the analyst consensus estimate of $(0.12) by 16.67 percent. This is a 16.67 percent decrease over los
Express News | Xeris Biopharma Reports First Quarter 2024 Financial Results and Recent Events
Express News | Xeris Biopharma Q1 Operating Income USD -14.245 Million
Express News | Xeris Biopharma Q1 Product Revenue USD 40.263 Million Vs. Ibes Estimate USD 41.8 Million
Xeris Biopharma 1Q Loss $19M >XERS
Xeris Biopharma 1Q Loss $19M >XERS